General Information:

Id: 3,890 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Fatty liver disease, nonalcoholic
Insulin resistance
Metabolic syndrome
Reference: Matikainen N and Taskinen MR(2012) Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes Curr Cardiol Rep 14: 721-731 [PMID: 22941588]

Interaction Information:

Comment Even after the most effective statin therapy and despite aggressive lifestyle interventions, a substantial number of subjects with MetS or T2D remain at high residual risk and obviously require add-on lipid lowering therapy that should be based on individual risk-benefit assessment.
Formal Description
Interaction-ID: 39365

drug/chemical compound


NOT decreases_activity of


Coronary artery disease

in part of the diabetic and metabolic syndrome patients, even in combination with intensive lifestyle intervention